Literature DB >> 7531297

Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis.

D Figarella-Branger1, A M Vagner-Capodano, P Bouillot, N Graziani, D Gambarelli, B Devictor, H Zattara-Cannoni, N Bianco, F Grisoli, J F Pellissier.   

Abstract

PDGFs and their receptors expression were examined in a series of 46 meningiomas by using specific monoclonal antibodies. The immunostaining was quantified by an image analyser and the results correlated with clinical and morphological data (histological type and grade). In addition, since the PDGFB chain is encoded by the c-sis proto-oncogene localized on chromosome 22 and because monosomy 22 has been frequently reported in meningiomas, PDGFs and PDGFRs expression have been correlated with cytogenetic analysis performed in 29 cases. The results demonstrate PDGF A and PDGF B expression in most meningioma specimens and co-expression of these growth factors in numerous cells. PDGF A and B immunoreactivity was related to histological grade. PDGFR beta expression was strong in almost all meningiomas whereas PDGFR alpha was low. PDGFR alpha expression was related to tumour location and grade and PDGFR beta to histological subtype only. The cytogenetic analysis was not related to PDGFB chain expression. Taken together these data further confirm PDGF and PDGFR expression in human meningioma; PDGF may exist as an heterodimer (AB) as well as its receptor. The lack of correlation between cytogenetic analysis and PDGF values, the low level of PDGFB in recurrent meningiomas suggests that it is unlikely that the c-sis proto-oncogene plays an important role in the genesis of meningiomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531297     DOI: 10.1111/j.1365-2990.1994.tb00994.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  7 in total

1.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

Review 2.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

3.  High throughput screening of meningioma biomarkers using a tissue microarray.

Authors:  Eriks A Lusis; Michael R Chicoine; Arie Perry
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

4.  Reactive hyperplasia of vascular pericytes in meningioma: immunohistochemical and ultrastructural studies of two cases.

Authors:  Masayuki Shintaku; Makoto Ohta; Hideo Chihara
Journal:  Int J Clin Exp Pathol       Date:  2022-08-15

5.  Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo.

Authors:  Tao Yu; Junguo Cao; Montadar Alaa Eddine; Mahmoud Moustafa; Andreas Mock; Cihan Erkut; Amir Abdollahi; Rolf Warta; Andreas Unterberg; Christel Herold-Mende; Gerhard Jungwirth
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

6.  Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.

Authors:  C Pfister; H Pfrommer; M S Tatagiba; F Roser
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

7.  PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.

Authors:  Matthieu Peyre; Céline Salaud; Estelle Clermont-Taranchon; Michiko Niwa-Kawakita; Stephane Goutagny; Christian Mawrin; Marco Giovannini; Michel Kalamarides
Journal:  Oncotarget       Date:  2015-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.